Thumbnail

亚太卵巢癌诊断和治疗市场 - 按癌症类型、癌症阶段、诊断、治疗和地理划分 - 增长、趋势、COVID-19 影响和预测(2021 - 2026 年)

Looking to buy the report?

在2018 年至 2023 年的预测期内,亚太地区卵巢癌诊断和治疗市场的复合年增长率预计为 12.4%。由于卵巢癌发病率的增加,预计中国将主导卵巢癌诊断和治疗市场。

卵巢癌发病率增加

根据世界卫生组织 (WHO) 的数据,亚洲每年诊断出超过 600 万例新癌症病例。癌症是导致死亡的主要原因,并且发病率每年都在增加。因此,对优质癌症治疗的需求急剧上升,这有助于市场的增长。根据香港卫生署的资料,卵巢癌是香港女性中第六大常见癌症,2014 年新增确诊病例 563 例,预计未来几年这一发病率将上升。因此,卵巢癌的增加正在推动亚太卵巢癌诊断和治疗市场的增长。

此外,更多地使用联合疗法治疗卵巢癌、老年妇女人口的增加以及发展中国家医疗保健支出的增加正在推动亚太地区卵巢癌诊断和治疗市场的增长。

卵巢癌缺乏准确诊断    

卵巢癌的准确诊断至关重要,因为在大多数情况下,癌症在诊断时已经开始扩散到淋巴结和骨盆外。Ovariancancerawareness.org 报告称,早期发现 1 期卵巢癌的 5 年生存率为 93%,大多数新发卵巢癌病例在 3 期或更晚时被诊断出来,几乎没有时间和准确诊断的空间。缺乏早期发现和准确诊断往往是由于卵巢癌症状经常被忽视,并且容易与其他疾病相混淆。这阻碍了亚太卵巢癌诊断和治疗市场的增长。此外,关键药物的专利到期也制约了亚太市场的增长。

中国主导市场

由于卵巢癌发病率的增加,中国在市场上占据主导地位。预计2015年中国将出现429万例癌症新发病例和281万例死亡病例。据估计,中国女性卵巢癌的发病率正在上升:在过去 10 年中,它增加了 30%,死亡率增加了 18%,每年有 15,000 人死亡。

                                                 

市场的主要发展

  • 2017 年 5 月 - 一种针对卵巢癌开发的新药ONX-0801处于第一阶段。

主要参与者包括 - Bristol Myers Squibb Company、Eli Lilly and Company、Glaxosmithkline Plc、Janssen Pharmaceuticals, Inc.、Genentech Inc.、Astra Zeneca Boehringer Ingelheim 和 F. Hoffman-La Roche Ltd 等。

购买报告的理由

  • 亚太卵巢癌诊断和治疗市场的市场分析,在全球和区域范围内进行区域特定的评估和竞争分析
  • 借助波特五力分析分析行业的各种观点
  • 预计将主导市场的治疗类型
  • 预计在预测期内增长最快的地区
  • 确定主要市场参与者采用的最新发展、市场份额和策略
  • 3 个月的分析师支持,以及市场估算表(Excel 格式)

报告的定制

  • 该报告可以定制以满足您的要求。请与我们的代表联系,他们将确保您获得适合您需求的报告。

1. Introduction

                1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

                5.1 Current Market Scenario

                5.2 Porter's Five Forces

                                5.2.1 Bargaining Power of Suppliers

                                5.2.2 Bargaining Power of Consumers

                                5.2.3 Threat of New Entrants

                                5.2.4 Threat of Substitute Product and Services

                                5.2.5 Competitive Rivalry Within the Industry

6. Drivers, Restraints, Opportunities And Challenges Analysis (DROC)

                6.1 Market Drivers

                                6.1.1 Increasing Incidence of Ovarian Cancer

                                6.1.2 Increasing Population of Aged Women

                                6.1.3 Greater Use of Combination Therapies for the Treatment of Ovarian Cancer               

                                6.1.4 Increase in Healthcare Expenditure in Developing Countries

                6.2 Market Restraints

                                6.2.1 Patent Expiry of Key Drugs

                                6.2.2 Lack of Accurate Diagnosis of Ovarian Cancer

                6.3 Opportunities

                6.4 Key Challenges

7.  Market Segmentation

                7.1 By Cancer Type

                                7.1.1 Epithelial Ovarian Tumors

                                7.1.2 Ovarian Germ Cell Tumors

                                7.1.3 Ovarian Stromal Tumors 

                                7.1.4 Primary Peritoneal Carcinoma

                7.2 By Cancer Stage

                                7.2.1 Stage I 

                                7.2.2 Stage II

                                7.2.3 Stage III 

                7.3 By Diagnosis

                                7.3.1 Physical Examination 

                                7.3.2 Biopsy

                                7.3.3 Blood Tests

                                7.3.4 Human Chorionic Gonadotropin (HCG) Test

                                7.3.5 Ultrasound 

                                7.3.6 PET

                                7.3.7 CT Scan

                                7.3.8 Others

                7.4 By Treatment

                                7.4.1 Chemotherapy

                                                7.4.1.1 Paclitaxel

                                                7.4.1.2 Docetaxel

                                                7.4.1.3 Cisplatin

                                                7.4.1.4 Carboplatin

                                                7.4.1.5 Others

                                7.4.2 Targeted Therapy 

                                                7.4.2.1 Bevacizumab

                                                7.4.2.2 Olaparib

                                7.4.3 Radiation Therapy

                                7.4.4 Immunotherapy

                                                7.4.4.1 Carboplatin

                                                7.4.4.2 Paclitaxel

                                7.4.5 Hormonal Therapy

                                                7.4.5.1 Goserelin

                                                7.4.5.2 Leuprolide

                7.5 By Geography

                                7.5.1 Asia-Pacific

                                                7.5.1.1 China

                                                7.5.1.2 Japan

                                                7.5.1.3 India

                                                7.5.1.4 Australia & New Zealand

                                                7.5.1.5 South Korea

                                                7.5.1.6 Rest of Asia-Pacific

8. Competitive Landscape

                8.1 Mergers and Acquisition Analysis

                8.2 Agreements, Collaborations & Partnerships

                8.3 New Products Launches

9. Key Players

                9.1 Astra Zeneca 

                9.2 Boehringer Ingelheim

                9.3 Bristol Myers Squibb Company

                9.4 Eli Lilly and Company

                9.5 F. Hoffman-La Roche Ltd

                9.6 Genentech Inc. 

                9.7 Glaxosmithkline Plc

                9.8 Janssen Pharmaceuticals, Inc.

                *List Not Exhausitive

10. Outlook of the Market

Looking to buy the report?

Need a report that reflects how COVID-19 has impacted this market and its growth?

Looking to customize report?

Email

Message

By submitting, you confirm that you agree to our privacy policy